deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT03466320

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.

Sponsor: Celyad Oncology SA

Conditions AML MDS
Interventions NKR-2
Updated 18 times since 2018 Last updated: Apr 30, 2021 Started: Sep 18, 2018 Primary completion: Feb 1, 2021 Completion: Feb 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates AML and MDS and is currently completed. Celyad Oncology SA leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  8. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  9. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Aug 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1

  11. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

  12. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE1

  13. Apr 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celyad Oncology SA
  • IQVIA Biotech
Data source: Celyad Oncology SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations